Professor Paul M Speight BDS, PhD, FDSRCPS, FDSRCS(Eng), FDSRCS(Edin), FRCPath
Dean, School of Clinical Dentistry
Professor in Oral Pathology, and Honorary Consultant Histopathologist

Department of Oral Pathology
School of Clinical Dentistry
University of Sheffield
Claremont Crescent
Sheffield
S10 2TA
Tel:+44 (0) 114 271 7951
Fax:+44 (0) 114 271 7894
email : p.speight@sheffield.ac.uk
Biography
I qualified in Dentistry at the University of Manchester in 1978, followed by house jobs and a MRC Clinical Training Fellowship at the University of Dundee, where I obtained a PhD in 1984. From 1983 -1984 I worked in Riyadh, Saudi Arabia, as an Oral Surgeon, and as Postgraduate Tutor, developing postgraduate education for junior hospital staff and teaching at the University Dental School. From 1984 to 2003 I worked in London, first at the Royal London Hospital Medical College and from 1990 to 2003 was Head of Oral & Maxillofacial Pathology at the Eastman Dental Institute, University College London.
I joined the University of Sheffield in 2003 when I took up the Chair in Oral Pathology. From September 2007 I have been Dean of the School.
I am a diagnostic histopathologist with special expertise in lesions of the jawbones, including odontogenic cysts, and salivary glands.
Research Interests
My research has been in understanding the pathobiology of oral disease, particularly trying to understand mechanisms of progression of oral cancer.
The pathobiology of oral cancer and cell adhesion molecules.
We have investigated the role of integrins and cadherins in oral cancer and in the modulation of epithelial cell behaviour. Although the emphasis has been on mechanisms of infiltration and progression of oral carcinomas, much of the work is of a basic biological nature and is equally applicable to other systems including wound healing. We characterised a series of cell lines and noted that some had lost specific integrin subunits.
Using DNA transfection techniques we have shown the importance of integrins in the regulation of epithelial cell function and have identified a particular integrin, alphaVbeta6, which can mediate cell migration, differentiation and metalloproteinase production and which may be fundamentally important in modulating the malignant phenotype and in normal wound healing. Current studies are investigating the central role of integrin-matrix interactions in a possible `feed-back loop mechanism´ which may potentiate cell migration and invasion.
Biomarkers in Oral Cancer and Salivary gland tumours
We are undertaking studies of minichromosome maintenance (MCM) proteins and cell proliferation markers in oral cancer and precancer. We have found that MCM2 and MCM5 are upregulated in oral dysplasia and in some salivary gland tumours. We have also shown that DNA ploidy analysis can predict which precancerous lesions may progress to oral cancer. On going studies include a prospective clinical trial of DNA analysis in cytology specimens from oral precancerous lesions.
Screening for oral cancer and precancer
In 1990 I established the UK Working Group on Screening for Oral Cancer and Precancer. This was a national group of experts who looked at the feasibility of screening for oral cancer. Subsequently I have sat on a number of national and international groups relating to oral cancer screening, including 3 UK Dept of Health advisory groups and an NIH working group. We have evaluated screening methods and have been concerned with the epidemiology of oral cancer in the UK, including a definitive description of increasing trends among younger people and the identification of alcohol as the most important factor mediating increased incidence of the disease. We have undertaken studies into the costs and benefits of oral cancer treatments and screening including quality of life studies and measurement of utility values and have shown that opportunistic screening of high risk individuals may be cost-effective. Recently we have investigated referral patterns of suspicious lesions from primary to secondary care, and have determined what factors influence a dentists decidion to refer patients with suspicious lesions.
Clinical research and case reports:
I have also made a significant contribution to my speciality of diagnostic pathology in the form of case series, reviews, basic clinical research and books.
- THOMAS GJ, LEWIS MP, HART IR, MARSHALL JF, SPEIGHT PM (2001) alphaVBeta6 integrin promotes invasion of squamous carcinoma cells through upregulation of matrix metalloproteinase-9. Int J Cancer, 92, 641 - 650
- THOMAS GJ, LEWIS MP, WHAWELL SA, RUSSELL A, SHEPPARD D, HART IR, SPEIGHT PM, MARSHALL JF (2001) Expression of the alphaVBeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol (in press)
- THOMAS GJ, POOMSAWAT S, LEWIS MP, HART IR, SPEIGHT PM, MARSHALL JF (2001) alphaVBeta6 integrin upregulates MMP-9 and promotes migration of normal oral keratinocytes. J Invest Dermatol 116, 898-904
- THOMAS GJ, HART IR, SPEIGHT PM, MARSHALL JF (2002)Binding of TGF-beta1 latency-associated peptide (LAP) to alphaVBeta6 integrin modulates behaviour of squamous carcinoma cells. British Journal of Cancer, 87, 859-86
- POOMSAWAT S, MORGAN MJ, WHAWELL SA, THOMAS GJ, SPEIGHT PM (2003) Scatter factor regulation of integrin expression and function on oral epithelial cells. Archs Dermatol Res, 295, 63-70
- LEWIS MP, LYGOE KA, NYSTROM ML, ANDERSON WP, SPEIGHT PM, MARSHALL JF, THOMAS GT (2004) Tumour-derived TGF--beta 1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Brit J Cancer 90, 822 – 832
- DALVI N, THOMAS GJ, MARSHALL JF, MORGAN M, BASS R, ELLIS V, SPEIGHT PM, WHAWELL S (2004 )Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit. Biochem Biophys Res Comm 317, 92-99
- NYSTROM ML, MCCULLOCH D, WEINREB PH, VIOLETTE SM, SPEIGHT PM, MARSHALL JF, HART IR, THOMAS GJ. (2006) Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 66:10833-10842.
Teaching Interests
My major role is teaching oral pathology to undergraduate and postgraduate students. I have special interest in cysts, oral cancer and salivary gland tumours.
As Dean of School I have oversight of all teaching and I am particularly concerned with maintaining a high quality education informed by excellence in research and scholarship.
Professional activities
I am a Past-President of the British Society for Oral and Maxillofacial Pathology, the International Association of Oral Pathologists, and the Oral Medeicine and Pathology Group of the IADR. From 2003 to 2008 I was Editor-in-Chief of Archives of Oral Biology and I still sit on 5 Editorial Boards, including being a senior adviser to the British Dental Journal. I am a member of numerous national and international committees including President of the British Society for Oral and Dental Research. In 2008 I was honoured with a Distinguished Scientist Award from the International Association for Dental Research.
Key Committees and administrative Roles
Local
Dean of School and Head of Department
Member, Faculty Executive Board
Member, Senate Budget Committee
National
President, British Society for Oral & Dental Research
Member, Dental Schools Council
NIHR Dean for Training (ACF) Advisory Panel
NIHR Research Fellowship Interview panels
NIHR National Oral and Dental Specialty Group
NCRI – Primary Care Clinical Studies Development Group
External Scientific Advisory Board, King´s Biomedical Research Centre
Oral & Dental Research Trust, advisory board
BDA, Central Committee for Academic Staff
BDA, Health and Science Committee
REF2014, Panel member
International
Member of Council of the International Association of Oral Pathologists
Editorial Board, J Oral Pathology and Medicine
Editorial Board, BMC Oral health
Scientific Advisory Board, Brit Dent Jour
International Advisory Board, J Oral Biosciences
International Review Panel. NIH Sjogren´s Syndrome (SICCA) project. UCSF
Expert Review Panel of Dental research, University of Hong Kong,
Key research papers
Pathobiology of oral cancer
- THOMAS GJ, LEWIS MP, HART IR, MARSHALL JF, SPEIGHT PM (2001) alphaVBeta6 integrin promotes invasion of squamous carcinoma cells through upregulation of matrix metalloproteinase-9. Int J Cancer, 92, 641 - 650
- THOMAS GJ, LEWIS MP, WHAWELL SA, RUSSELL A, SHEPPARD D, HART IR, SPEIGHT PM, MARSHALL JF (2001) Expression of the alphaVBeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol, 117:67-73
- THOMAS GJ, POOMSAWAT S, LEWIS MP, HART IR, SPEIGHT PM, MARSHALL JF (2001) alphaVBeta6 integrin upregulates MMP-9 and promotes migration of normal oral keratinocytes. J Invest Dermatol 116, 898-904
- THOMAS GJ, HART IR, SPEIGHT PM, MARSHALL JF (2002)Binding of TGF-beta1 latency-associated peptide (LAP) to alphaVBeta6 integrin modulates behaviour of squamous carcinoma cells. British Journal of Cancer, 87, 859-86
- POOMSAWAT S, MORGAN MJ, WHAWELL SA, THOMAS GJ, SPEIGHT PM (2003) Scatter factor regulation of integrin expression and function on oral epithelial cells. Archs Dermatol Res, 295, 63-70
- LEWIS MP, LYGOE KA, NYSTROM ML, ANDERSON WP, SPEIGHT PM, MARSHALL JF, THOMAS GT (2004) Tumour-derived TGF--beta 1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Brit J Cancer 90, 822 – 832
- DALVI N, THOMAS GJ, MARSHALL JF, MORGAN M, BASS R, ELLIS V, SPEIGHT PM, WHAWELL S (2004 )Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit. Biochem Biophys Res Comm 317, 92-99
- NYSTROM ML, MCCULLOCH D, WEINREB PH, VIOLETTE SM, SPEIGHT PM, MARSHALL JF, HART IR, THOMAS GJ. (2006) Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 66:10833-10842.
Biomarkers in Oral cancer and salivary gland tumours
- VARGAS PA, TORRES-RENDON A, SPEIGHT PM. (2007) DNA ploidy analysis in salivary gland tumours by image cytometry. J Oral Pathol Med. 36:371-6.
- VARGAS PA, SPEIGHT PM, BINGLE CD, BARRETT AW, BINGLE L. (2008) Expression of PLUNC family members in benign and malignant salivary gland tumours. Oral Dis 14:613-9
- TORRES-RENDON A, STEWART R, CRAIG GT, WELLS M, SPEIGHT PM. (2008). DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol. 45: 468-73
- TORRES-RENDON A, ROY S, CRAIG GT, SPEIGHT PM. (2009) Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Brit J Cancer, 7:1128-34.
Oral cancer screening and early detection
- MOLES DR, DOWNER MC, SPEIGHT PM (2002) Meta-analysis of measures of performance reported in oral cancer and precancer screening studies. Brit Dent J, 192, 340-344
- LIM K, MOLES DR, DOWNER MC, SPEIGHT PM (2003) Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. Br Dent J, 194, 497-502
- DOWNER MC, MOLES DR, PALMER S, SPEIGHT PM (2004) A systematic review of test performance in screening for oral cancer and precancer Oral Oncology 40, 264-273
- DOWNER MC, MOLES DR, PALMER S, SPEIGHT PM. (2006) A systematic review of measures of effectiveness in screening for oral cancer and precancer. Oral Oncol.42:551-560.
- SPEIGHT PM, PALMER S, MOLES DR, DOWNER MC, SMITH DH, HENRIKSSON M, AUGUSTOVSKI F (2005). The cost-effectiveness of screening for oral cancer in primary care. Health Technology Assessment 10 (14). 1-144
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM. (2009) Factors affecting the referral of potentially malignant lesions from primary dental care: a pilot study in South Yorkshire. Prim Dent Care. 16:13-8.
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM (2010). A qualitative study examining the experience of primary care dentists in the detection and management of potentially malignant lesions. 2. Mechanics of the referral and patient communication. Br Dent J 23: 208(2):E4; 74-5.
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM (2010). A qualitative study examining the experience of primary care dentists in the detection and management of potentially malignant lesions. 1. Factors influencing detection and the decision to refer. Br Dent J 23: 208(2):E3; 72-3
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM (2010). Factors which determine the referral of potentially malignant disorders by primary care dentists. Journal of Dentistry 38:569-578.
Clincal cases series and reviews
- SASAKI T, MOLES DR, IMAI Y, SPEIGHT PM (2005) Clinico-pathological features of squamous cell carcinoma of the oral cavity in patients under 40 years of age. J Oral Pathol Med 34, 129 – 133.
- LINGEN MW, KALMAR JR, KARRISON T, SPEIGHT PM (2008)
- Critical evaluation of diagnostic aids for the the detection of oral cancer. Oral Oncology 44; 10-22
- NAPIER SS, SPEIGHT PM (2008) Natural History of Potentially Malignant Disorders: An overview of the literature. J Oral Pathol Med 37; 1-10
- SPEIGHT PM, BARRETT AW. (2009) Diagnostic difficulties in lesions of the minor salivary glands. Diagnostic Histopathology 15: 311-317
- JORDAN RCK, SPEIGHT PM (2009) Current concepts of odontogenic tumours. Diagnostic Histopathology 15: 303-310
- SPEIGHT PM, BARRETT AW (2009) Prognostic factors in malignant tumours of the salivary glands (Leading article). Brit J Oral Maxfac Surg 47: 587-593
- BARRETT AW, SPEIGHT PM (2009) Perineural invasion in adenoid cystic carcinoma of the salivary glands: a valid prognostic indicator? Oral Oncology 45: 936-940
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM (2010).
- Oral cancer screening: what have we learnt and what is there still to achieve? Future Oncol 6:299-304.
- BROCKLEHURST PR, BAKER SR, SPEIGHT PM (2010). Primary care clinicians and the detection and referral of potentially malignant disorders in the mouth: a summary of the current evidence. Prim Dent Care 17(2):65-71
- BARRETT AW, SPEIGHT PM. (2011) Perineural invasion in adenoid cystic carcinoma of the salivary glands: anatomical influences on oncological management. Current Cancer Therapy Rev 7: 78-82.
